Targeting mammalian target of rapamycin (mTOR) for health and diseases

Drug Discov Today. 2007 Feb;12(3-4):112-24. doi: 10.1016/j.drudis.2006.12.008. Epub 2006 Dec 15.


The macrolide rapamycin is used clinically to treat graft rejection and restenosis. Mammalian target of rapamycin (mTOR) is a central controller of cellular and organism growth that integrates nutrient and hormonal signals, and regulates diverse cellular processes. New studies have linked mTOR to several human diseases including cancer, diabetes, obesity, cardiovascular diseases and neurological disorders. Recent data have also revealed that mTOR is involved in the regulation of lifespan and in age-related diseases. These findings demonstrate the importance of growth control in the pathology of major diseases and overall human health, and underscore the therapeutic potential of the mTOR pathway.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Aging / drug effects
  • Animals
  • Chronic Disease / drug therapy
  • Drug Delivery Systems*
  • Drug Design
  • Humans
  • Immunosuppressive Agents / pharmacology*
  • Life Expectancy
  • Protein Kinases / drug effects
  • Protein Kinases / physiology*
  • Sirolimus / agonists*
  • Sirolimus / pharmacology*
  • TOR Serine-Threonine Kinases


  • Immunosuppressive Agents
  • Protein Kinases
  • MTOR protein, human
  • TOR Serine-Threonine Kinases
  • Sirolimus